Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.

doi:10.1158/1078-0432.CCR-25-2566

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 16 Mar 2026

Yeh Celine, Artz Oliver, Zhang Haochen, Karnoub Elias-Ramzey, Ntiamoah Peter, Weipert Caroline, Walch Henry, Harrold Emily, Keane Fergus, Chalasani Sree, Segal Neil H, Foote Michael B, Cercek Andrea, Pagano Andrew, Maron Steven B, Diaz Luis A, Iacobuzio-Donahue Christine A, Shia Jinru, Rousseau Benoit, Yaeger Rona

Abstract excerpt

PURPOSE: Microsatellite stable (MSS) colorectal cancers, in contrast to microsatellite instability-high colorectal cancers, have few mutations and are insensitive to immune checkpoint blockade (ICB). Colorectal cancers treated with targeted agents often acquire a high number of genomic alterations at progression. We asked whether targeted therapy could be used to generate a high tumor mutational burden (TMB) in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Colorectal Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Lymphocytes, Tumor-Infiltrating

Share to Microsatellite Instability

Share to Molecular Targeted Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 41165465
DOI: 10.1158/1078-0432.CCR-25-2566
PMCID: PMC13012239

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.PMID 41165465Read ↗

Tumor mutational burden predicts neoantigen profiles and immunotherapy response in microsatellite stable tumors across different cancer types.Semantic proximity Read ↗

Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer.Semantic proximity Read ↗

High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology.Semantic proximity Read ↗

The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancersSemantic proximity Read ↗

Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.Semantic proximity Read ↗

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibitionSemantic proximity Read ↗

Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives.Semantic proximity Read ↗

High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.Semantic proximity Read ↗

Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens.Semantic proximity Read ↗

Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomesSemantic proximity Read ↗

Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal CancerSemantic proximity Read ↗

Tumor mutational burden in colorectal cancer: Implications for treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.